We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Lovenox Approval Provides Insight Into Biosimilars Approach
Generic Lovenox Approval Provides Insight Into Biosimilars Approach
August 3, 2010
The FDA’s rationale for approving the first generic version of Sanofi-Aventis’ blood thinner Lovenox provides a glimpse into how the agency may act in implementing an approval pathway for biosimilar drugs.